1-(4-氟苯基甲基)哌嗪 | 27064-89-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(4-氟苯基甲基)哌嗪
• 英文名称: (+)-1-[(4-fluorophenyl)phenylmethyl)piperazine
• 英文别名: 1-(p-Fluor-α-phenylbenzyl)-piperazin；1-((4-Fluorophenyl)(phenyl)methyl)piperazine；1-[(4-fluorophenyl)-phenylmethyl]piperazine
• CAS: 27064-89-7
• 化学式: C₁₇H₁₉FN₂
• 分子量: 270.35
• InChiKey: KKMSCNTZDCYNSC-UHFFFAOYSA-N

物化性质

• 熔点：
  82-84°C
• 沸点：
  366.7±37.0 °C(Predicted)
• 密度：
  1.126±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  1-(4-氟苯基甲基)哌嗪 在 氯甲酸乙酯 作用下， 生成 (E)-N-[4-[4-[(4-fluorophenyl)-phenylmethyl]piperazin-1-yl]butyl]-3-pyridin-3-ylprop-2-enamide
  参考文献：
  名称：

  Acrylamide derivatives as antiallergic agents. 2. Synthesis and structure activity relationships of N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3-(3-pyridyl)acrylamides

  摘要：

  A new series of 3-(3-pyridyl)acrylamides 16, 17, 19, and 26, and 5-(3-pyridyl)-2,4-pentadienamides 20-25 were prepared and evaluated for their antiallergic activity. Several of these compounds exhibited more potent inhibitory activities than the parent compound 1a [(E)-N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3- (3-pyridyl)acrylamide] against the rat passive cutaneous anaphylaxis (PCA) reaction and the enzyme 5-lipoxygenase. Particularly, (E)-N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3- (6-methyl-3-pyridyl)acrylamide (17p) showed an ED50 value of 3.3 mg/kg po in the rat PCA test, which was one-fifth of ketotifen and oxatomide. As compared with ketotifen and oxatomide, compound 17p (AL-3264) possessed a better balance of antiallergic properties due to inhibition of chemical mediator release, inhibition of 5-lipoxygenase, and antagonism of histamine.

  DOI：

  10.1021/jm00123a012
• 作为产物：
  描述：

  4-氟二苯甲醇 在 氯化亚砜 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 1-(4-氟苯基甲基)哌嗪
  参考文献：
  名称：

  Synthesis and Anticancer Activity of 1-(1H-Indol-3-yl)-2-(4-diarylmethylpiperazine-1-yl)ethane-1,2-dione Derivatives

  摘要：

  通过对1-二芳甲基哌嗪与2-(1H-吲哚-3-基)-2-氧乙酰氯化物的酰化反应，合成了几种新的1-(4-二芳甲基哌嗪-1-基)-2-(1H-吲哚-3-基)乙烷-1,2-二酮衍生物。它们的结构经过1H核磁共振、红外光谱、质谱和元素分析确认。这些化合物进一步评估了它们的抗癌活性，大多数化合物对Hela、A-549和ECA-109癌细胞系表现出中等至强的抗增殖活性。

  DOI：

  10.1155/2016/4617454

文献信息

• Aminopyrimidine Kinase Inhibitors
  申请人：Baldino Carmen M.

  公开号：US20110152235A1

  公开（公告）日：2011-06-23

  Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of casein kinase 1 (e.g., CK1γ), casein kinase 2 (CK2), Pim 1, Pim2, Pim3, the TGFβ pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of casein kinase 1 (e.g., CK1γ), casein kinase 2 (CK2), Pim 1, Pim2, Pim3, the TGFβ pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway.

  揭示了化合物、含有这些化合物的药物组合物，以及这些化合物和组合物作为酪蛋白激酶1（例如CK1γ）、酪蛋白激酶2（CK2）、Pim 1、Pim2、Pim3、TGFβ途径、Wnt途径、JAK/STAT途径和/或mTOR途径调节剂的用途。还揭示了用于治疗或预防一系列治疗适应症的用途，至少部分原因是由于酪蛋白激酶1（例如CK1γ）、酪蛋白激酶2（CK2）、Pim 1、Pim2、Pim3、TGFβ途径、Wnt途径、JAK/STAT途径和/或mTOR途径的异常生理活性。
• [EN] NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS<br/>[FR] NOUVEAUX COMPOSÉS UTILISÉS COMME BLOQUEURS DES CANAUX CALCIQUES
  申请人：ABBOTT LAB

  公开号：WO2010039947A1

  公开（公告）日：2010-04-08

  The present application relates to calcium channel inhibitors containing compounds of formula (I) wherein Ar1, Ar2, L1, L2, n, R1, R4, X and Y are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

  本申请涉及含有式（I）化合物的钙通道抑制剂，其中Ar1、Ar2、L1、L2、n、R1、R4、X和Y如规范中所定义。本申请还涉及包含这些化合物的组合物，以及使用这些化合物和组合物治疗疾病和疾病的方法。
• HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST
  申请人：Okada Makoto

  公开号：US20130085127A1

  公开（公告）日：2013-04-04

  A heterocyclic compound useful as an antiallergic agent is provided. A compound represented by the following formula (1) or a salt thereof: wherein the ring A is a homocyclic or heterocyclic ring; the ring B is a heterocyclic ring which contains G and nitrogen atom N as constituent atoms thereof, wherein G is CH or N; R 1 is a carbonyl group or an alkylene group; R 2a and R 2b are an alkyl group, a cycloalkyl group, an aryl group, or a heterocyclic group; X is an oxygen atom or a sulfur atom; Z is a hydroxyl group, an alkoxy group, a cycloalkyloxy group, an aryloxy group, an aralkyloxy group, an amino group, or an N-substituted amino group; and n is 0 or 1; with the proviso that when the ring A is a benzene ring or when the ring B is a piperazine ring, R 1 is an alkylene group which may have a substituent.

  提供一种作为抗过敏剂使用的杂环化合物。所述化合物由以下式（1）或其盐表示：其中环A是同环或杂环；环B是一个杂环，其中包含G和氮原子N作为其组成原子，其中G是CH或N；R1是一个羰基或一个烷基基团；R2a和R2b是烷基基团、环烷基基团、芳基团或杂环基团；X是一个氧原子或硫原子；Z是一个羟基、烷氧基、环烷氧基、芳氧基、芳基氧基、氨基或N-取代氨基；n为0或1；但条件是当环A为苯环或环B为哌嗪环时，R1是可能有取代基的烷基基团。
• 1-[(Heterocyclyl)-alkyl]-4-diarylmethoxy piperidine derivatives
  申请人：Janssen Pharmaceutica, N.V.

  公开号：US04200641A1

  公开（公告）日：1980-04-29

  Novel 1-[(heterocyclyl)alkyl]-4-diarylmethoxy piperidine derivatives are disclosed having the formula ##STR1## where n is 2-6, Ar.sup.1 and Ar.sup.2 are aryl and B is a substituted benzimidazolyl radical. These compounds are useful for their antianaphylactic and antihistaminic properties. Specific claimed compounds are 1-3-[4-(diphenylmethoxy)-1-piperidinyl]-propyl}-1,3-dihydro-2H-benzimidaz ol-2-one, 1-2-[4-(diphenylmethoxy)-1-piperidinyl]ethyl}1-, 3-dihydro-2H-benzimidazol-2-one, and 1-4-[4-(diphenylmethoxy)-1-piperidinyl]butyl}-1,3-dihydro-2H-benzimidazol -2-one.

  Novel 1-[(heterocyclyl)alkyl]-4-diarylmethoxy piperidine derivatives are disclosed having the formula ##STR1## where n is 2-6, Ar.sup.1 and Ar.sup.2 are aryl and B is a substituted benzimidazolyl radical. These compounds are useful for their antianaphylactic and antihistaminic properties. Specific claimed compounds are 1-3-[4-(diphenylmethoxy)-1-piperidinyl]-propyl}-1,3-dihydro-2H-benzimidaz ol-2-one, 1-2-[4-(diphenylmethoxy)-1-piperidinyl]ethyl}1-, 3-dihydro-2H-benzimidazol-2-one, and 1-4-[4-(diphenylmethoxy)-1-piperidinyl]butyl}-1,3-dihydro-2H-benzimidazol -2-one.
• Pyrrolidine Carboxamides as a Novel Class of Inhibitors of Enoyl Acyl Carrier Protein Reductase from <i>Mycobacterium tuberculosis</i>
  作者：Xin He、Akram Alian、Robert Stroud、Paul R. Ortiz de Montellano

  DOI：10.1021/jm060715y

  日期：2006.10.1

  of Mycobacterium tuberculosis, there is an urgent need to discover antituberculosis agent with novel structures. InhA, the enoyl acyl carrier protein reductase (ENR) from M. tuberculosis, is one of the key enzymes involved in the mycobacterial fatty acid elongation cycle and has been validated as an effective antimicrobial target. We report here the discovery, through high-throughput screening, of

  鉴于结核分枝杆菌的多药耐药性在世界范围内的传播，迫切需要发现具有新颖结构的抗结核药。InhA是结核分枝杆菌的烯酰基酰基载体蛋白还原酶（ENR），是分枝杆菌脂肪酸延长周期中涉及的关键酶之一，已被证实是有效的抗菌靶标。我们在此报告通过高通量筛选发现的一系列吡咯烷羧酰胺，它们是一类新的强效InhA抑制剂。与三种抑制剂复合的InhA晶体结构已用于阐明抑制剂的结合模式。通过迭代微量滴定文库合成的后续优化，然后不经纯化就地进行活性筛选，可将先导化合物的效能提高160倍以上。